NCT00005858View on ClinicalTrials.gov

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Bladder CancerBreast CancerColorectal CancerLung CancerOvarian CancerPancreatic Cancer
Interventions
BIOLOGICAL

LMB-9 immunotoxin

Trial Locations (2)

21201

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT00005858 - LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | Biotech Hunter | Biotech Hunter